SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT03226223

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse

This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will assess the ability of oral NTX to block the reinforcing and positive subjective effects of intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse pharmacotherapy.

NCT03226223 Substance Use Disorders Methamphetamine Abuse
MeSH:Substance-Related Disorders

1 Interventions

Name: Intranasal Methamphetamine

Description: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
Type: Drug
Group Labels: 2

Naltrexone 0 mg Naltrexone 50 mg

Primary Outcomes

Description: To assess the reinforcing effects of methamphetamine, participants complete a drug vs. money self-administration procedure. The outcome measure for this procedure is their percentage of choices for drug (methamphetamine) choices.

Measure: Percentage of methamphetamine choices.

Time: 1 day.

Secondary Outcomes

Description: Participant ratings of methamphetamine "Liking," on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates "Not at All," while the 100 mm indicates "Extremely."

Measure: Positive subjective effects of methamphetamine.

Time: 1 day

Purpose: Basic Science

Allocation: Randomized

Crossover Assignment

There is one SNP


1 rs1799971

Substance Use Disorders Methamphetamine Abuse Substance-Related Disorders A recent meta-analysis concluded that the OPRM1 A118G SNP (rs1799971) significantly moderates the treatment efficacy of Naltrexone (NTX) in treating alcohol abuse, increasing the treatment efficacy by over 2-fold among G-allele carriers (AG/GG).

HPO Nodes